Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
HSDT vs PHIO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
HSDT Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–3 Matrix Metrics)
HSDT Overall Winner
6-Pillar Tally: HSDT 4 – 1 PHIO (1 Tie)
Matrix Metrics: HSDT 7 – 3 PHIO
As of Nov 20, 2026, Solana Company (HSDT) is the stronger overall head-to-head candidate over Phio Pharmaceuticals Corp. (PHIO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HSDT carries a Unified Composite Score of 47.2/100 (HOLD) at $1.49 (N/M Forward P/E, -1557.5% operating margin), whereas PHIO carries 41.2/100 (SELL) at $0.66 (0.3x Forward P/E, 0.0% operating margin).
- Technical & Structure Timing Caution: HSDT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 24.3); meanwhile PHIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About HSDT vs PHIO
HSDT
Head-to-Head Winner
Solana Company Class A Common Stock (DE)
$1.49
-10.24% 1D
Market Cap
$104.4M
TTM Revenue
$271M
Forward P/E
N/M
Beta / 30D Vol
2.22β · 60% Vol
Unified Composite Score
47.2
HOLD
Tech 25.0
Fund 58.0
Flow 68.0
Mom 59.0
Weinstein Technical Phase
Markdown · Sell / avoid
PHIO
Phio Pharmaceuticals Corp. Common Stock
$0.66
-8.25% 1D
Market Cap
$8.5M
TTM Revenue
N/A
Forward P/E
0.3x
Beta / 30D Vol
1.07β · 57% Vol
Unified Composite Score
41.2
SELL
Tech 25.0
Fund 46.0
Flow 50.0
Mom 59.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (HSDT 4 – 1 PHIO)
1. Valuation Multiples
HSDT
Forward P/E
N/M
0.3x
Trailing P/E
0.0x
0.3x
PEG Ratio
N/M
N/M
EV / Revenue
0.4x
N/M
2. Growth & Scale
HSDT
Revenue Growth (YoY)
+382.1%
+0.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$271M
N/A
Market Cap
$104.4M
$8.5M
3. Profitability & Quality
HSDT
Gross Margin
92.8%
N/A
Operating Margin
-1557.5%
0.0%
Net Profit Margin
2040.4%
0.0%
Return on Equity (ROE)
52.8%
-159.0%
4. Balance Sheet & Cash Flow
HSDT
Cash Generation (TTM)
-$4.21B EBITDA
-$11M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$4.38 Book/Sh · 52.8% ROE
$0.72 Book/Sh · -159.0% ROE
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
PHIO
Options Structure Phase
BREAKDOWN
UNCLASSIFIED
Current IV / %ile
540.7% (85th %ile)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
DISTRIBUTION · Markdown
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
High-Margin Pricing Power Moat
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Asset Management Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: HSDT (7) vs PHIO (3)| Institutional Metric | HSDT | PHIO | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $104.4M | $8.5M | HSDT | |
| Trailing P/E Ratio | 0.0x | 0.3x | HSDT | |
| Forward P/E Ratio | N/M | 0.3x | PHIO | |
| Revenue Growth (YoY) | +382.1% | +0.0% | HSDT | |
| Operating Margin (TTM) | -1557.5% | 0.0% | PHIO | |
| Net Profit Margin | 2040.4% | 0.0% | HSDT | |
| Return on Equity (ROE) | 52.8% | -159.0% | HSDT | |
| 52-Week Range Position | 10% ($1–$4) | 1% ($1–$2) | HSDT | |
| Beta / 30D Volatility | 2.22β · 60% Vol | 1.07β · 57% Vol | PHIO | |
| Unified Institutional Score | 47.2 / 100 (HOLD) | 41.2 / 100 (SELL) | HSDT | |
| Trailing 12M Revenue (USD) | $271M | N/A | Scale | |
| Gross Profit Margin (TTM) | 92.8% | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 0.4x EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$4.21B EBITDA ($4.38 Book/Sh · 52.8% ROE) | -$11M ($0.72 Book/Sh · -159.0% ROE) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
PHIO +9.26 pp
3M Horizon
HSDT +12.28 pp
6M Horizon
HSDT +4.89 pp
1Y Horizon
PHIO +12.85 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | HSDT Revenue | PHIO Revenue | HSDT Op. Margin | PHIO Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $0M | $0M | -5580.5% | -5336.2% | PHIO |
| FY2019 | $0M | $0M | -1604.0% | -42795.2% | HSDT |
| FY2020 | $0M | N/A | -2176.4% | N/A | HSDT |
| FY2021 | $0M | N/A | -3679.9% | N/A | HSDT |
| FY2022 | $0M | N/A | -1994.3% | N/A | HSDT |
| FY2023 | $0M | N/A | -2054.2% | N/A | HSDT |
| FY2024 | $0M | N/A | -2673.7% | N/A | HSDT |
| FY2025 | $0M | N/A | -44496.4% | N/A | HSDT |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
HSDT
BREAKDOWN
Current IV
540.7%
IV Percentile
85th %ile
Put/Call OI Skew
N/A
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact HSDT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
PHIO
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact PHIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
HSDT Moat Profile
High-Margin Pricing Power Moat
Asset Management Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
PHIO Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ HSDT vs PHIO Key Questions & Quantitative Answers
As of Nov 20, 2026, Solana Company (HSDT) is the stronger overall head-to-head candidate over Phio Pharmaceuticals Corp. (PHIO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HSDT carries a Unified Composite Score of 47.2/100 (HOLD) at $1.49 (N/M Forward P/E, -1557.5% operating margin), whereas PHIO carries 41.2/100 (SELL) at $0.66 (0.3x Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: HSDT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 24.3); meanwhile PHIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
HSDT leads the Growth & Scale pillar: HSDT posts +382.1% YoY revenue growth and +0.0% YoY earnings growth on $271M TTM revenue (92.8% gross margin, -1557.5% operating margin), compared with PHIO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), HSDT cumulative revenue shifted N/A while PHIO shifted N/A. In operating R&D and SG&A reinvestment, HSDT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PHIO.
HSDT screens cheaper on headline valuation multiples. HSDT trades at N/M Forward P/E, 0.0x Trailing P/E, N/M PEG, and 0.4x EV/Revenue (unreported EBITDA margin), whereas PHIO trades at 0.3x Forward P/E, 0.3x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HSDT (52.8% ROE) versus PHIO (-159.0% ROE) capital efficiency.
In options market volatility and institutional positioning, HSDT carries 540.7% implied volatility (85th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.22β · 60% Vol realized risk). By comparison, PHIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.07β · 57% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
PHIO vs HSDT · Reverse Pair
HSDT vs QNRX
· Sector Peer
HSDT vs NUWE
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal